Literature DB >> 1519850

Studies on the role of tumor necrosis factor in adult respiratory distress syndrome.

P E Parsons1, F A Moore, E E Moore, D N Iklé, P M Henson, G S Worthen.   

Abstract

Tumor necrosis factor (TNF), rapidly becoming recognized as a mediator of inflammation, may be important in the pathogenesis of acute lung injury. Its role in the development of the adult respiratory distress syndrome (ARDS) in humans, however, has been difficult to clarify. To determine if TNF could be important early in the development of acute lung injury from multiple causes, we enrolled 103 patients within 8 h of meeting the criteria for an at-risk illness (sepsis, aspiration of gastric contents, severe pancreatitis, hypertransfusion, abdominal trauma, chest trauma, multiple fractures) and obtained multiple frequent blood samples for TNF measurements. Using five methods of TNF analysis, we were unable to find an association between TNF and the development of ARDS. However, we found significant differences in TNF measurements depending on the methods of analysis used, which could, at least in part, account for the inconsistencies in the published literature regarding the relationship between TNF and disease processes.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1519850     DOI: 10.1164/ajrccm/146.3.694

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  14 in total

1.  Death receptors mediate the adverse effects of febrile-range hyperthermia on the outcome of lipopolysaccharide-induced lung injury.

Authors:  Anne B Lipke; Gustavo Matute-Bello; Raquel Herrero; Venus A Wong; Stephen M Mongovin; Thomas R Martin
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2011-04-22       Impact factor: 5.464

2.  Inflammatory cytokines enhance the interaction of Mannheimia haemolytica leukotoxin with bovine peripheral blood neutrophils in vitro.

Authors:  F Leite; S O'Brien; M J Sylte; T Page; D Atapattu; C J Czuprynski
Journal:  Infect Immun       Date:  2002-08       Impact factor: 3.441

Review 3.  Biomarkers in acute lung injury.

Authors:  Maneesh Bhargava; Chris H Wendt
Journal:  Transl Res       Date:  2012-02-07       Impact factor: 7.012

Review 4.  Inflammatory predictors for the development of the adult respiratory distress syndrome.

Authors:  P T Reid; S C Donnelly; C Haslett
Journal:  Thorax       Date:  1995-10       Impact factor: 9.139

5.  Comparison of systemic cytokine levels in patients with acute respiratory distress syndrome, severe pneumonia, and controls.

Authors:  T T Bauer; C Montón; A Torres; H Cabello; X Fillela; A Maldonado; J M Nicolás; E Zavala
Journal:  Thorax       Date:  2000-01       Impact factor: 9.139

Review 6.  Pharmacotherapy of acute lung injury and acute respiratory distress syndrome.

Authors:  Krishnan Raghavendran; Gloria S Pryhuber; Patricia R Chess; Bruce A Davidson; Paul R Knight; Robert H Notter
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

7.  Circulating tumor necrosis factor alpha (TNF), soluble TNF receptors, and interleukin-6 in human subacute bacterial endocarditis.

Authors:  W V Kern; A Engel; S Schieffer; O Prümmer; P Kern
Journal:  Infect Immun       Date:  1993-12       Impact factor: 3.441

8.  Kinetics and correlation with body temperature of circulating interleukin-6, interleukin-8, tumor necrosis factor alpha and interleukin-1 beta in patients with fever and neutropenia.

Authors:  A Engel; W V Kern; G Mürdter; P Kern
Journal:  Infection       Date:  1994 May-Jun       Impact factor: 3.553

9.  Induction of inflammatory cytokines in bovine alveolar macrophages following stimulation with Pasteurella haemolytica lipopolysaccharide.

Authors:  H S Yoo; S K Maheswaran; G Lin; E L Townsend; T R Ames
Journal:  Infect Immun       Date:  1995-02       Impact factor: 3.441

10.  Blood lactate levels are better prognostic indicators than TNF and IL-6 levels in patients with septic shock.

Authors:  G Marecaux; M R Pinsky; E Dupont; R J Kahn; J L Vincent
Journal:  Intensive Care Med       Date:  1996-05       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.